The Ultimate Guide to FDA Cybersecurity Guidelines for Medical Devices

The FDA cybersecurity guidelines outline the principles for medical device security design, pre-market risk documentation and post-market security vulnerability management. The latest FDA final guidance from 3 February 2026 covers threat modelling, labelling, testing, security architecture and quality management, as well as premarket submissions. The Federal Food, Drug, and Cosmetic Act (FD&C Act) imposes certain new legal obligations on any device that falls within the definition of a “cyber device” in Section 524B. 

This guide outlines which requirements are applicable, provides information on the type of evidence required for a 510(k), De Novo and PMA submission, and what manufacturers must carry out after authorization.

What Are the FDA Cybersecurity Guidelines for Medical Devices?

The FDA's cybersecurity guidelines are the agency's guidance for addressing cybersecurity risks that may affect a medical device's safety and effectiveness. They cover how manufacturers identify threats, design security controls, test their products, document their findings, and manage vulnerabilities throughout the device's lifecycle.

The main reference is the FDA's final guidance, Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, issued on February 3, 2026. This replaces the June 27, 2025, version.

The guidance applies to cybersecurity issues related to device software, hardware, firmware, and connected systems that may impact safety or effectiveness. It also covers cloud-powered devices and devices with artificial intelligence.

There are two things that should be understood.

• First, the guidance is non-binding recommendations. It reflects FDA's current thinking and the evidence that FDA recommends manufacturers submit.
• Second, Section 524B of the Federal Food, Drug, and Cosmetic Act sets forth the statutory criteria for qualified cyber devices. These rights and duties are not recommendations that manufacturers can choose not to comply with.

This is important if you are making a regulatory submission. A manufacturer must know which laws apply and what the recommendations are in relation to the design of the device, the risks it faces regarding cybersecurity, and the environment in which the device will be used.

What are the key FDA cybersecurity requirements for 2026?

For medical device manufacturers, this framework incorporates the FDA guidance on cybersecurity, as well as the quality management requirements in place for the product life cycle, plus the statutory obligations under Section 524B, if applicable.

The relevant FDA documents are the 2026 cybersecurity guidance, Quality Management System Regulation, Postmarket Management of Cybersecurity in Medical Devices, and Content of Premarket Submissions for Device Software Functions.

Manufacturers must make use of the most up-to-date versions of the documents which are relevant to their device and submission pathway, not the previous checklists which may not reflect the guidance issued in February 2026.

What Does Section 524B REALLY Require? 

There are three core cybersecurity requirements for qualifying cyber devices as set forth in Section 524B.

1. A plan to monitor and address cybersecurity vulnerabilities

Manufacturers need to have a strategy to identify, track, and rectify vulnerabilities and exploits in their products within a reasonable timeframe. This includes coordinated vulnerability disclosure and related procedures.

A written plan should specify who receives vulnerability reports, how the manufacturer assesses the reports, what sources they track, and what steps they take to report vulnerability findings throughout the investigation, assessment, remediation, and communication process.

2. Security processes and timely updates/patches.

Manufacturers need to develop processes and procedures to ensure that the device and related systems are reasonably secure.

Section 524B also differentiates between required expedient remediation timing:

• Acceptable vulnerabilities identified: Updates and patches need to be provided on a reasonably justifiable timeframe.
• Any critical vulnerabilities that could lead to uncontrolled risks: Updates and patches need to be provided as quickly as possible, outside the normal update and patch cycle.

There is no general deadline for patches for all devices. Manufacturers must have a defensible approach that acknowledges the vulnerability, potential consequences, device function, and risk to the patient.

3. A Software Bill of Materials

Manufacturers are responsible for providing an SBOM for commercial, open-source and off-the-shelf software components.

When a software component is found to have a new vulnerability, the SBOM can be used to determine which other devices and systems might be vulnerable. But creating a list of components is not enough to perform effective lifecycle management. There should be a way for manufacturers to keep an accurate software inventory as the software evolves.

The FDA recommends evidence to meet these statutory requirements, which are described in Section VII of the guidance.

Which Medical Devices Fall Under Section 524B?

Section 524B is applicable to cyber devices that are statutorily defined. There are three factors that FDA uses to determine if a device is part of this definition.

1. The software on the device is software that the sponsor validates, installs or authorizes as a device or in a device.
2. The device has access to the Internet.
3. The device has technological features that are susceptible to a cyber security attack.

The three elements are all relevant to the determination. Manufacturers need to analyse the actual device architecture, connectivity, software and intended use of a product, rather than assuming them from a product marketing description.

Examples could include infusion pumps that are connected, patient monitoring devices, networked imaging devices, networked diagnostic devices, and other devices with software and connectivity that satisfy the statutory requirements. A software product regulated as a medical device may also warrant assessment.

Internet connectivity deserves particular attention. The FDA's 2026 guidance identifies network, server, and cloud connections; Wi-Fi; cellular communication; Bluetooth and Bluetooth Low Energy; magnetic inductive communication; and hardware connectors capable of connecting to the internet as examples to consider.

What type of submissions does the FDA include?

The FDA's Section 524B FAQ contains the following paths for cyber device submissions:

• 510(k) submissions (including Special 510(k) and Abbreviated 510(k) submissions)
• Pre-Market Approval (PMA) (with supplements)
• Product Development Protocol (PDP)
• De Novo
• Humanitarian Device Exemption (HDE) with any applicable supplements.

This law is not applicable to submissions prior to March 29, 2023. If a cyber device that had been previously authorized is modified, and the modification is subject to a new submission for premarket approval, then Section 524B applies to the new submission, subject to the applicable requirements.

Manufacturers assessing a legacy device should therefore consider its original authorization, subsequent changes, and the submission requirements associated with those changes. The FDA's Cybersecurity in Medical Devices FAQ explains these distinctions.

What Documentation Should Be Included in an FDA Cybersecurity Premarket Submission?

An FDA cybersecurity premarket submission should include evidence of identification, assessment, mitigation, and management of the cybersecurity risks of a medical device throughout its lifecycle. Below are 14 categories of documentation that can assist manufacturers in structuring this evidence based upon the FDA's current cybersecurity guidance.

1. Security Architecture

Architecture documentation for security is the process of creating a record of the medical device system, its components, external interfaces, communication paths, trust boundaries, and security controls implemented. It should describe how the device connects to hospital networks, cloud services, external applications and other connected systems as appropriate and how it is secured from known threats.

2. Threat Modeling Report

A threat modeling report will detail potential threats, attack pathways, vulnerable assets, and the impact of these assets on device safety and effectiveness. It should include the entire medical device system and include any risk associated with the development, production, deployment, software updates, interoperability, maintenance and decommissioning of the device, as well as the assumptions and mitigations performed in the assessment.

3. Software Bill of Materials 

An SBOM serves as a list of software components that can be proprietary, commercial, or open-source that have been used in the creation of a medical device. The SBOM is mandated for qualifying cyber devices under Section 524B. The FDA recommends machine-readable SBOMs that comply with the minimum elements set forth by the NTIA to assist manufacturers in determining if their product has been compromised by new vulnerabilities.

4. Software Level of Support and End of Support

This documentation will point out if software is currently maintained, no longer supported, or abandoned, and the end-of-support date. This information is useful to manufacturers to determine which dependencies are not supported, how this may affect the cybersecurity risks, and how to properly facilitate the element being replaced or updated throughout the device's intended service life.

5. Penetration Testing Report

A penetration testing report documents the assessment scope, duration, methods, tester expertise and independence, findings, identified vulnerabilities, and the manufacturer's remediation decisions. The FDA suggests providing the original report when testing is done by a third party.

6. Retesting Report

A retesting report is a document that documents the verification that is carried out after cybersecurity vulnerabilities have been mitigated. It should correlate each Finding with the Corrective Action taken, describe the retest procedure and the result, and determine if the vulnerability has been remediated or is still to be addressed. The evidence supports that fixes implemented are successful and do not create any extra security or functional problems.

7. Security Assessment of Unresolved Anomalies

This evaluation identifies unresolved software anomalies that may affect, when submitted, the safety, effectiveness and cyber security of the device. It should take into account if there is an anomaly that could be exploited, any relevant Common Weakness Enumeration (CWE) categories, the risks, and the reasons for not fixing the issue or not resolving it.

8. Cybersecurity Risk Assessment

A cybersecurity risk assessment involves assessing known threats and vulnerabilities with regard to the medical device and operating environment. It takes into account the likelihood of an exploit, consequences, implemented controls, and remaining risks following the implementation of controls. The assessment shall support the decision to either determine that risks are successfully mitigated and acceptable or that they are not. The assessment shall include references to the corresponding evidence of threat modelling, testing and risk management.

9. Safety and security risk assessment of vulnerabilities

This assessment evaluates each known Vulnerability within the device and software elements considered, and their potential impact on the device and the broader connected system. The document should record how the vulnerability was identified, describe its impact on patient safety and device effectiveness, and specify appropriate safety and security controls. It should fully explain the compensating controls.

10. Cybersecurity Controls

Cybersecurity control documentation defines the security controls that have been put in place to mitigate the risks found in the threat modelling and risk assessment process. They can encompass authentication, authorization, cryptography, code integrity, data integrity, confidentiality, event detection and logging, resiliency and recovery, and secure software and firmware updates. How relevant controls are applied and how effectiveness is ensured should be explained in the documentation.

11. Cybersecurity Risk Management Report

A cybersecurity risk management report summarizes risk identification, assessment, mitigation, residual risks, and decisions, linking threat modeling, SBOM, vulnerability assessments, component support data, unresolved anomalies, and test results. The report captures these together to help determine the safety and effectiveness of devices.

12. Cybersecurity Labelling

Cybersecurity labeling offers information to users to install, configure, operate and maintain the medical device safely. It can include network requirements, security configurations, user access, compatible configurations, software updates, known cybersecurity threats, and any applicable instructions for addressing security concerns. The information should be suitable for the device used, and be suitable for the people using it.

13. Cybersecurity Metrics

Cybersecurity metrics enable manufacturers to track how effective their security processes are across the device lifecycle. The FDA says they should monitor data including the percentage of vulnerabilities that they know and have patched, the time between when they discover a vulnerability and when they patch it, and the time between when they make the patch available in the field and when they deploy it. They can use these measures to detect delays and to improve the vulnerability management process.

14. Cybersecurity Risk Management Plan

A cybersecurity risk management plan defines how manufacturers identify, assess, control, and monitor risks throughout a device’s lifecycle, including responsibilities, vulnerability disclosure, monitoring, and security update processes. The plan and relevant procedures must include the obligations and requirements of the FD&C Act Section 524B for cyber devices.

FDA Cybersecurity SBOM Requirements: What Manufacturers Need to Know

SBOM is a list of the software products that are included in a product. For medical devices, it assists their manufacturers in identifying if a vulnerability found in a third-party library, operating system or dependency impacts the device.

Section 524B mandates that SBOMs be included in the premarket MedTech cybersecurity requirements for qualifying cyber devices. SBOM documentation is also a general recommendation for FDA as a cybersecurity risk management measure.

The following areas should all be addressed in a useful SBOM process.

1. Component identification: Add software developed by the system owner, third party, commercial, open source, and upstream software components.
2. Machine-readable information: FDA guidance suggests the use of SBOMs that conform to the minimum elements outlined in a 2021 document from the National Telecommunications and Information Administration (NTIA), Framing Software Component Transparency: Establishing a Common Software Bill of Materials (SBOM).
3. Recommendations for support status: FDA recommends that you include details about the level of monitoring and maintenance support for each software component from its manufacturer and the end-of-support date for the software. This information could be part of a SBOM or provided outside of it.
4. Known vulnerabilities: List known vulnerabilities of the device and software elements. The FDA specifically references vulnerabilities identified in the CISA's Known Exploited Vulnerabilities Catalog and references the need to outline how known vulnerabilities are found and evaluated.
5. Maintenance: Update the SBOM as software components change. It should also facilitate the manufacturer's vulnerability assessment, risk management and remediation process after the device has been released to the market.

An SBOM is not a compliance document that anyone simply generates for submission. When a vulnerability is uncovered after authorization, the manufacturer must determine which products contain the affected component and whether there is a risk of device harm or ineffectiveness.

Why SBOM Data Quality is important in 2026

A practical problem is that component names and identifiers may vary across software inventories, scanners, supplier records, and SBOM tools. Those inconsistencies can make it difficult to determine whether two records refer to the same component or version.

On April 22, 2026, MITRE published Considerations for Managing Challenges in Software Bill of Materials (SBOM) Data Normalization. The paper covers the topic of SBOM processing, inconsistent data and tooling, and the benefit of having a consistent source of information for components.

For manufacturers, the practical lesson is to establish a reliable process for reconciling component identifiers and versions across software inventories and vulnerability-management tools. A machine-readable SBOM is useful only when the organization can interpret it and connect its records to the actual product.

What Does the FDA Expect in a Medical Device Penetration Test?

• Penetration testing is a way to find out if there are any holes or vulnerabilities that can be exploited in the product or surrounding area. It can be used in conjunction with threat modeling, code analysis, vulnerability scanning and verification of individual security controls.
• The FDA guidance for 2026 cautions that penetration testing be a component of the cybersecurity testing and outlines information to be provided in penetration-test reports.
• Assess the device's intended environment and attack surface, including interfaces, authentication, remote access, updates, exposed services, cloud connections, and external system interactions.
• The manufacturer then has to consider the results when determining the safety and effectiveness of the device. The fact that a finding has not resulted in a known incident should not be used to dismiss it as a finding that is not yet resolved. The assessment should describe its vulnerability, risk, possible impact, and possible mitigations/dispositions.
• FDA does not have a single, universal recipe for penetration testing of medical devices. The scope of the test and the evidence should mirror the architecture of the system, threats identified, controls put in place and risks. The guidance also doesn't stipulate that an outside penetration testing firm will always have to test every device. It encourages documentation of tester expertise and independence, and suggests that third-party testing might be needed if a level of independence cannot otherwise be achieved.

How Should Manufacturers Manage Cybersecurity After FDA Authorization?

Medical device cybersecurity is not a one-time event, but ongoing. Over time the security of a device can be compromised by new software vulnerabilities, changes in external systems, unsupported dependencies, and new methods of exploiting weaknesses in existing systems.

The FDA's Postmarket Management of Cybersecurity in Medical Devices guidance outlines proposed recommendations for the management of vulnerabilities in marketed and distributed devices.

The postmarket process should be clearly defined and owned, with actions outlining how it will be monitored, triaged, remediated, verified and communicated to the rest of the industry.

Monitor vulnerability information

Monitor pertinent advisories, supplier alerts, security research, and vulnerability lists. The CISA’s Known Exploited Vulnerabilities Catalog is especially relevant since it highlights vulnerabilities that have been exploited in “the wild.”

You can't assume that if a component is in an advisory, then a vulnerability exists in a device. They should explore the presence, version, setting, exposure and potentially impacts of the component.

Evaluate risk to patients and devices in operation

Identify if the vulnerability impacts device use, confidentiality or integrity of information, system availability or clinical workflows.

The device needs to be evaluated in its context as part of a risk assessment. A potential vulnerability that can be seen as contained in a single device may be more serious if it can be exploited to gain access to other systems or cause disruption to several devices.

Create and validate patches

Software can behave differently in security updates, or interact with safety-critical functions. Manufacturers should therefore review the proposed remediation, ensure that it is addressing the vulnerability, and consider whether it brings in new vulnerabilities.

This process should also cover non-airplay devices that are hard to remotely update, need clinical coordination or have limited connectivity.

Section 524B requires regular patching of known unacceptable vulnerabilities and timely updates for critical vulnerabilities that pose uncontrolled risks.

Communicate with customers and disclose vulnerabilities

Manufacturers need to have protocols for external reports and for coordinating vulnerability disclosure. These procedures should ensure the identification of the team(s) responsible for reporting on the assessment process and how to communicate mitigations and remediation.

Clear information should be provided to healthcare providers about the devices that are potentially affected, the interim actions to take and when an update is available.

A postmarket plan is better if it outlines these roles before an incident rather than leaving teams to figure it out during a security incident.

What impact does the FDA's QMSR have on Medical Device Cybersecurity in 2026?

The Quality Management System Regulation will enter into force on February 2, 2026. It amends 21 CFR Part 820 and incorporates ISO 13485:2016 by reference, bringing the FDA's device quality management requirements into closer alignment with the international standard.

Why is the change important: Cyber security is not an isolated issue of product safety, product design controls, product risk management, product change management, and product corrective action.

As part of the FDA's guidance for cybersecurity in 2026, they talk about a Secure Product Development Framework (SPDF) as one way to assist with cybersecurity risk management and QMSR compliance. FDA recommends that manufacturers employ an SPDF, but does not require a specific SPDF. Other methods can also be used to achieve the QMSR if they are found to meet the relevant requirements.

Manufacturers should be able to show a connection between recognized cybersecurity risks and design decisions, security controls, verification outcomes, residual risk assessments, approved changes, and postmarket actions in practice.

If a supplier discontinues software support, manufacturers must assess security risks, determine mitigation or replacement needs, and document decisions in quality processes.

The effective date and requirements are posted on FDA's QMSR resource page.

What Changed in FDA Medical Device Cybersecurity in 2026?

Three trends are especially important for the regulatory and product security groups.

February 3, 2026: The FDA issued updated cybersecurity guidance

The current final guidance replaced the June 27, 2025, edition. Manufacturers should use the February 2026 document when preparing new submissions or reviewing existing cybersecurity documentation against the current recommendations.

This should be the starting point for any 2026 assessment of FDA cybersecurity submission readiness.

February 2, 2026: QMSR became effective

Manufacturers need to account for the new QMSR framework and its incorporation of ISO 13485:2016 by reference. Cybersecurity risk management should connect with the organization's quality system, not operate as an isolated technical activity.

April 22, 2026: MITRE published research on evolving technology risks

In its paper, Cybersecurity Risk Analysis for Medical Devices in the Era of Evolving Technologies, MITRE examines considerations for cybersecurity in the context of cloud computing, AI/ML, and post-quantum cryptography.

These topics matter as devices increasingly rely on external services, software components, data connections, and emerging technologies. The paper is a technical resource, not a new FDA regulation.

MITRE also published the SBOM data-normalization paper discussed earlier. Both publications can help manufacturers strengthen their technical processes, but they do not replace the FDA's official guidance or statutory requirements.

October 2026: Healthcare operational resilience remains relevant

On October 9, 2026, HHS's ASPR TRACIE updated its Cybersecurity Topic Collection, highlighting incident response, downtime planning, and continuity of patient care.

This resource is not a new FDA device requirement, but is instead about healthcare preparedness. It is still, however, applicable for manufacturers to think about what security incidents on their devices might mean for clinical operations and what to instruct users to do when their systems go offline.

The FDA's February 2026 final cybersecurity guidance is the primary cybersecurity reference document identified in the FDA's listing of cybersecurity guidance as of October 14, 2026.

Common Pitfalls in FDA Cybersecurity Submissions

There are a lot of questions that can remain unanswered even with a lot of security documents. The following issues should be of special concern to manufacturers.

1. Treating cybersecurity as a final-stage test. Security needs to be considered during design, architecture, risk management, and development, not added only when a submission is being assembled.
2. Providing a scan report without a risk assessment. A list of findings does not explain whether vulnerabilities could affect device safety, whether mitigations are effective, or why unresolved findings are acceptable.
3. Submitting an incomplete or outdated SBOM. Missing software versions, unidentified dependencies, unsupported components, or inconsistent component records can make vulnerability impact assessment difficult.
4. Ignoring connected systems. Assessing the device in isolation may overlook risks from cloud services, external programmers, hospital networks, remote support, and other systems needed for operation.
5. Leaving patching responsibilities unclear. The manufacturer should establish who monitors vulnerabilities, who decides when remediation is necessary, how updates are validated, and how users receive them.
6. Failing to document remediation decisions. Deferred findings require a reasoned assessment. An unexplained decision to leave a vulnerability unresolved makes it difficult to understand how the manufacturer has managed the risk.
7. Using an outdated regulatory checklist. A checklist based on the June 2025 guidance may not reflect the current February 2026 document or the QMSR framework now in effect.

A clearly documented process that connects the architecture, risk assessment, controls, test evidence, software inventory, and postmarket responsibilities of the device is the best approach to these issues.

FDA Cybersecurity Readiness Checklist for Medical Device Manufacturers

When preparing a 510(k), De Novo, PMA, or other premarket application, please check the following points against the current FDA guidance and specific requirements for your device.

Product design and risk management

• The team has considered the device to be a cyber device.
• The safety and effectiveness of devices have been assessed against cyber risks.
• Threat modeling applies to the system of devices, interfaces, dependencies and environment.
• Documentation of security architecture provides information about the applicable connections, boundaries and controls.
• Security controls are verified and validated to be suitable for the identified risks.

Software inventory and testing

• A SBOM is a list of applicable software components and their associated dependencies.
• Machine-readable and compliant with FDA recommendations for required SBOM information.
• Support and End-of-support information have been evaluated for components.
• Any identified vulnerabilities have been assessed for their applicability and severity.
• Testing records include scope, methods, results, findings and remediation decisions.
• Reporting on penetration testing covers the expertise of the testers, independence of the testers, the scope of testing, its duration, and results.

Submission and lifecycle management

• The submission covers Section 524B in which the device and submission reside.
• The cybersecurity management plan identifies vulnerability monitoring and coordinated disclosure procedures.
• Procedures cover patch development, validation, release and customer communication.
• Relevant information is included on the label to enable users to safely operate and maintain the device.
• Cybersecurity activities are included in the relevant quality management system.
• The team has reviewed the current FDA guidance and submission format for its pathway.

The following checklist is indicative and not intended to be a complete replacement of the assessment of the device-specific requirements. The quantity and level of evidence should be proportional to the device's nature and the cybersecurity risks identified and the regulatory pathway.

Preparing for an FDA 510(k) Submission?

Generate FDA-compliant SBOMs, VEX documentation, and cybersecurity assessments with expert support.

Speak with Our FDA Compliance Team →

Conclusion

A vulnerability scan or a group of security policies isn't enough for FDA cybersecurity compliance. Manufacturers will need to demonstrate the methods used to identify cyber threats, the actions they take to address the threats, the evaluation of results, and after authorization security measures.

This work is guided primarily by the FDA guidance (section 524B) for February 2026, and the QMSR framework. They make it important to tie product security to design controls, software inventory management, testing evidence, vulnerability disclosure, and postmarket updates.

Before submitting to the FDA, review your device documentation against current guidance, identify gaps, and assign responsibility for addressing them.

Frequently Asked Questions 

1. What is the latest FDA cybersecurity guidance for medical devices?

The latest principal final guidance from the FDA is Cybersecurity in Medical Devices: Quality Management System Considerations and Content of Premarket Submissions, released Feb. 3, 2026. It replaces the version dated 27th June 2025, covering cybersecurity design, quality management, and documentation prior to the market introduction.

2. Are FDA cybersecurity guidelines mandatory?

The recommendations in the guidance are non-binding. However, the statutory requirements in Section 524B of the FD&C Act cover qualifying cyber devices. Manufacturers have a duty to differentiate recommendations from obligations imposed by legislation or other relevant regulations.

3. Does every medical device need an SBOM?

Under Section 524B, an SBOM must be provided for any cyber devices for which the standard applies. The FDA also calls for SBOM documentation to be part of a broader cybersecurity risk management. Manufacturers should decide on the requirements for their device and submission.

4. Does the FDA require penetration testing for medical devices?

The FDA guidance that has been issued is updated and suggests penetration testing and outlines information for penetration testing reports. It also suggests other types of security testing and analysis. Risks, architecture and security controls are at the heart of the testing programme, and should be based on more than just one universal test procedure.

5. What is Section 524B of the FD&C Act?

Section 524B introduces cybersecurity requirements for certain cyber devices. These include plans and procedures for vulnerability monitoring, identification, and mitigation postmarket vulnerabilities, updates and patches of identified vulnerabilities, and an SBOM. The FDA currently has guidance on cybersecurity that covers the applicable duties.

6. What is the relationship between FDA cybersecurity guidance and ISO 13485?

QMSR will come into effect on 2 February 2026 and will reference ISO 13485:2016. The FDA Cybersecurity Guidance describes the relationship of cybersecurity activities to the quality management system. The Secure Product Development Framework is one method that FDA recommends manufacturers may follow, but is not the only way to comply with applicable QMSR requirements.